Comparison · NCT04552899-e7519ddc
Zinpentraxin Alfa vs Placebo: Percentage of Participants Permanently Discontinuing Study Treatment Due to AEs
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Zinpentraxin Alfa vs Placebo: Percentage of Participants Permanently Discontinuing Study Treatment Due to AEs. Trial comparisons, record NCT04552899-e7519ddc. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04552899-e7519ddc
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0272 | 0.0144 | 0.0509 | wilson | |
| Risk in group 2 | 0.0182 | 0.00838 | 0.0392 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00895 | -0.0156 | 0.0346 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.49 | 0.537 | 4.14 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.529 | 4.28 | log | |
| Number needed to treat, for one more participant with the outcome on Zinpentraxin Alfa than on Placebo | 112 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Zinpentraxin Alfa | Participants received intravenous (IV) infusions of Zinpentraxin Alfa over 50-70 minutes on Days 1, 3 and 5, then followed by infusions every 4 weeks (Q4W) to Week 48. | 9 | 331 | OG000 |
| Group 2 | Placebo | Participants received IV infusions of placebo over 50-70 minutes on Days 1, 3 and 5, followed by infusions Q4W to Week 48. | 6 | 329 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Participants Permanently Discontinuing Study Treatment Due to AEs
- Description
- Time frame
- From Baseline up to 8 weeks after the last dose of study drug (up to an average of 1 year)
- Population
- The safety population included all randomized participants who received at least one administration (full or partial dose) of study drug and were grouped according to the actual treatment received.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
- NCT number
- NCT04552899
- Phases
- PHASE3
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151 (Zinpentraxin Alfa), Placebo
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2024-04-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04552899?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04552899-e7519ddc